Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVEO PHARMACEUTICALS, INC.AVEO · Entity 120602 | Chief Financial Officer | February 06, 2019 | February 08, 2019 |
| Harvard Apparatus Regenerative Technology, Inc.BSTG · Entity 7501 | Director | June 03, 2019 | June 05, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVEO PHARMACEUTICALS, INC.
Report date February 06, 2019 · Filed February 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2029-02-06 | Direct | 450,750 |
Reported balance
After 2019-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-06 · Grant · Acquired 450,750 · Balance 450,750 F1: The shares underlying this option vest in equal monthly installments from February 6, 2019 through February 6, 2023, subject to the Reporting Person's continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in equal monthly installments from February 6, 2019 through February 6, 2023, subject to the Reporting Person's continued service to the Company.
Harvard Apparatus Regenerative Technology, Inc.
Report date June 03, 2019 · Filed June 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2029-06-03 | Direct | 10,364 |
Reported balance
After 2019-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-03 · Grant · Acquired 10,364 · Balance 10,364 F1: This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 3, 2019, December 3, 2019, March 3, 2020, and June 3, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2029-06-03 | Direct | 18,775 |
Reported balance
After 2019-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-06-03 · Grant · Acquired 8,411 · Balance 18,775 F2: This Stock Option was granted in lieu of 2019 cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2019, September 30, 2019, and December 31, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 3, 2019, December 3, 2019, March 3, 2020, and June 3, 2020.
F2: This Stock Option was granted in lieu of 2019 cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2019, September 30, 2019, and December 31, 2019.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CoLucid Pharmaceuticals, Inc.
Report date March 01, 2017 · Filed March 01, 2017
Section 16 reporting ended · disclosed 2017-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2017-03-01 · Other · Disposed 2,708 · Balance 0 F1: Includes 80 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through February 19, 2017. F2: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these shares were tendered pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2017-03-01 · Disposition to issuer · Disposed 37,500 · Balance 0 F3: These restricted stock units, which by their terms were convertible into common stock of the Issuer on a one-for-one basis, vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2025-05-05 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-03-01 · Disposition to issuer · Disposed 180,254 · Balance 0 F4: These options, which provided that 25% of the shares vested on May 5, 2016, and the remaining shares vesting in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.56 · Expires 2025-08-04 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-03-01 · Disposition to issuer · Disposed 30,000 · Balance 0 F5: These options, which provided that 25% of the shares vested on August 4, 2016, and the remaining shares vesting in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.75 · Expires 2026-03-04 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-03-01 · Disposition to issuer · Disposed 37,500 · Balance 0 F6: These options, which provided for vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 80 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through February 19, 2017.
F2: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these shares were tendered pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest.
F3: These restricted stock units, which by their terms were convertible into common stock of the Issuer on a one-for-one basis, vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest.
F4: These options, which provided that 25% of the shares vested on May 5, 2016, and the remaining shares vesting in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
F5: These options, which provided that 25% of the shares vested on August 4, 2016, and the remaining shares vesting in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
F6: These options, which provided for vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2019 Filed Jun 5, 2019 16:32 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 8,411 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001144204-19-029895 · tv523168_form4.xml · derivative · entry 2 Dallas Matthew D · CIK 0001612396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,775 Underlying: Common Stock, par value $0.01 per share · 8,411 shares Expires 2029-06-03 F2 · derivative.exercise_date: This Stock Option was granted in lieu of 2019 cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2019, September 30, 2019, and December 31, 2019. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:32 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 10,364 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001144204-19-029895 · tv523168_form4.xml · derivative · entry 1 Dallas Matthew D · CIK 0001612396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,364 Underlying: Common Stock, par value $0.01 per share · 10,364 shares Expires 2029-06-03 F1 · derivative.exercise_date: This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 3, 2019, December 3, 2019, March 3, 2020, and June 3, 2020. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 16:31 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 450,750 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000899243-19-003035 · doc4.xml · derivative · entry 1 Dallas Matthew D · CIK 0001612396 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,750 Underlying: Common Stock · 450,750 shares Expires 2029-02-06 F1 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from February 6, 2019 through February 6, 2023, subject to the Reporting Person's continued service to the Company. Read SEC document |
| November 13, 2018 Filed Nov 15, 2018 19:06 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 10,897 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001144204-18-060325 · tv507434_form4.xml · derivative · entry 1 Dallas Matthew D · CIK 0001612396 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,897 Underlying: Common Stock, par value $0.01 per share · 10,897 shares Expires 2028-11-13 F1 · derivative.exercise_date: The Stock Option shares will vest in four equal installments on February 13, 2019, May 13, 2019, August 13, 2019, and November 13, 2019. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 19:57 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000899243-18-002740 · doc4.xml · derivative · entry 1 Dallas Matthew D · CIK 0001612396 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-02-01 F1 · derivative.exercise_date: The shares underlying this option vest in equal monthly installments from February 1, 2018, through February 1, 2022, subject to the Reporting Person's continued service to the Company. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 16:30 UTC | AVEO PHARMACEUTICALS, INC. AVEO · Entity 120602 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0000899243-17-017790 · doc4.xml · derivative · entry 1 Dallas Matthew D · CIK 0001612396 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2027-07-03 F1 · derivative.exercise_date: 25% of this option shall vest on June 1, 2018, and the remainder of this option shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Company. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:12 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 37,500 | $39.75 Strike: $6.75 | $1,490,625.00 |
DisclosureSEC source: 0000911916-17-000068 · edgar.xml · derivative · entry 5 Dallas Matthew D · CIK 0001612396 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2026-03-04 F6 · derivative.exercise_date: These options, which provided for vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:12 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $38.94 Strike: $7.56 | $1,168,200.00 |
DisclosureSEC source: 0000911916-17-000068 · edgar.xml · derivative · entry 4 Dallas Matthew D · CIK 0001612396 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2025-08-04 F5 · derivative.exercise_date: These options, which provided that 25% of the shares vested on August 4, 2016, and the remaining shares vesting in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:12 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 180,254 | $36.50 Strike: $10.00 | $6,579,271.00 |
DisclosureSEC source: 0000911916-17-000068 · edgar.xml · derivative · entry 3 Dallas Matthew D · CIK 0001612396 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 180,254 shares Expires 2025-05-05 F4 · derivative.exercise_date: These options, which provided that 25% of the shares vested on May 5, 2016, and the remaining shares vesting in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:12 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerCommon Stock | 37,500 | $46.50 | $1,743,750.00 |
DisclosureSEC source: 0000911916-17-000068 · edgar.xml · nonDerivative · entry 2 Dallas Matthew D · CIK 0001612396 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: These restricted stock units, which by their terms were convertible into common stock of the Issuer on a one-for-one basis, vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:12 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | OtherCommon Stock | 2,708 | $46.50 | $125,922.00 |
DisclosureSEC source: 0000911916-17-000068 · edgar.xml · nonDerivative · entry 1 Dallas Matthew D · CIK 0001612396 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 80 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through February 19, 2017. F2 · price: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these shares were tendered pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 16:24 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | SaleCommon Stock | 1,473 | $36.25 | $53,396.25 |
DisclosureSEC source: 0000911916-17-000026 · edgar.xml · nonDerivative · entry 1 Dallas Matthew D · CIK 0001612396 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,128 F1 · shares: Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Dallas on August 15, 2016. One purpose of the plan is to sell shares of common stock acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan. Read SEC document |
| December 01, 2016 Filed Dec 1, 2016 16:43 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | SaleCommon Stock | 1,473 | $35.17 | $51,801.14 |
DisclosureSEC source: 0000911916-16-000693 · edgar.xml · nonDerivative · entry 1 Dallas Matthew D · CIK 0001612396 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,601 F1 · shares: Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Dallas on August 15, 2016. One purpose of the plan is to sell shares of common stock acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan. F2 · price: Represents the sale of 1,473 shares in multiple transactions, ranging in price from $35.00 to $35.45 per share, resulting in a weighted average sale price of $35.1671. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes 5,574 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through November 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.